Contrasting Legend Biotech (NASDAQ:LEGN) and Inhibrx Biosciences (NASDAQ:INBX)

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) and Legend Biotech (NASDAQ:LEGN – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.

Volatility and Risk

Inhibrx Biosciences has a beta of 4.03, suggesting that its stock price is 303% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Insider & Institutional Ownership

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Inhibrx Biosciences and Legend Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inhibrx Biosciences N/A -563.90% -80.38%
Legend Biotech -0.02% -0.03% -0.02%

Valuation & Earnings

This table compares Inhibrx Biosciences and Legend Biotech”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inhibrx Biosciences $2.00 million 509.31 -$140.05 million ($9.06) -7.61
Legend Biotech $1.36 billion 2.18 -$296.80 million ($0.01) -1,525.00

Inhibrx Biosciences has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Inhibrx Biosciences and Legend Biotech, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibrx Biosciences 1 2 2 1 2.50
Legend Biotech 1 6 9 0 2.50

Inhibrx Biosciences presently has a consensus price target of $185.00, indicating a potential upside of 168.23%. Legend Biotech has a consensus price target of $48.64, indicating a potential upside of 218.97%. Given Legend Biotech’s higher possible upside, analysts clearly believe Legend Biotech is more favorable than Inhibrx Biosciences.

Summary

Inhibrx Biosciences beats Legend Biotech on 8 of the 14 factors compared between the two stocks.

About Inhibrx Biosciences

(Get Free Report)

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.

About Legend Biotech

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.

Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.